2021 KUMC Virtual Multidisciplinary Oncology Review


 

IO Updates for MSS & HER2 Overexpression CRC: Nivo Alone or in Combination for CC, Regorafenib+Nivo for mCRC, Bev+Chemo, Trastuzumab+Lapatinib/Pertuzumab in HER2+ Disease

21 views
May 17, 2021
0 Comments
Login to view comments. Click here to Login
Videos